BYSI
HEALTHCAREBeyondSpring Inc
$1.55+0.11 (+7.64%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BYSI Today?
No stock-specific AI insight has been generated for BYSI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.21$3.44
$1.55
Fundamentals
Market Cap$64M
P/E Ratio—
EPS$-0.21
Dividend Yield—
Dividend / Share—
ROE-3.1%
Profit Margin—
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding41.1M
BYSI News
16 articles- BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC DrugsYahoo Finance·Apr 22, 2026
- Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn SituationYahoo Finance·Apr 6, 2026
- BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026Yahoo Finance·Mar 30, 2026
- BeyondSpring Files 2025 Annual Report on Form 10-KYahoo Finance·Mar 25, 2026
- BeyondSpring Reports 2025 Year-End Financial ResultsYahoo Finance·Mar 25, 2026
- BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° ConferenceYahoo Finance·Feb 9, 2026
- BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration PathYahoo Finance·Dec 12, 2025
- BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025Yahoo Finance·Dec 11, 2025
- BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn SituationYahoo Finance·Oct 28, 2025
- BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership AppointmentYahoo Finance·Aug 13, 2025
- BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor FailureYahoo Finance·Jul 7, 2025
- BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual MeetingYahoo Finance·Jun 3, 2025
- BeyondSpring Announces Poster Presentation at 2025 ASCO Annual MeetingYahoo Finance·May 28, 2025
- Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?Yahoo Finance·May 15, 2025
- BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·May 12, 2025
All 16 articles loaded
Price Data
Open$1.48
Previous Close$1.44
Day High$1.50
Day Low$1.37
52 Week High$3.44
52 Week Low$1.21
52-Week Range
$1.21$3.44
$1.55
Fundamentals
Market Cap$64M
P/E Ratio—
EPS$-0.21
Dividend Yield—
Dividend / Share—
ROE-3.1%
Profit Margin—
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding41.1M
About BeyondSpring Inc
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—